Information Provided By: 
Fly News Breaks for May 4, 2015
CBM
May 4, 2015 | 09:56 EDT
Longbow said the pullback in Cambrex following the Q1 report and guidance is a buying opportunity. CBM raised its revenue outlook for generic SBU to low to mid single digit growth from low single digits, has strong demand for Hep-C therapies, reduced FX headwinds, and is well positioned to raise guidance.
News For CBM From the Last 2 Days
There are no results for your query CBM
